Oostveen Reindert F, Kaiser Yannick, Stroes Erik S G, Verberne Hein J
Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Department of Radiology and Nuclear Medicine, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Pharmaceuticals (Basel). 2022 Jun 30;15(7):812. doi: 10.3390/ph15070812.
Aortic valve stenosis (AVS) is an increasingly prevalent disease in our aging population. Although multiple risk factors for AVS have been elucidated, medical therapies capable of slowing down disease progression remain unavailable. Molecular imaging technologies are opening up avenues for the non-invasive assessment of disease progression, allowing the assessment of (early) medical interventions. This review will focus on the role of positron emission tomography of the aortic valve with F-fluorodeoxyglucose and F-sodium fluoride but will also shed light on novel tracers which have potential in AVS, ranging from the healthy aortic valve to end-stage valvular disease.
主动脉瓣狭窄(AVS)在老龄化人群中是一种日益普遍的疾病。尽管已经阐明了AVS的多种风险因素,但仍没有能够减缓疾病进展的医学疗法。分子成像技术为疾病进展的非侵入性评估开辟了途径,从而能够评估(早期)医学干预措施。本综述将重点关注使用F-氟脱氧葡萄糖和F-氟化钠对主动脉瓣进行正电子发射断层扫描的作用,但也将介绍在AVS中具有潜力的新型示踪剂,范围从健康的主动脉瓣到终末期瓣膜疾病。